Objective To investigate the expression of aryl hydrocarbon receptor (AhR) mRNA in peripheral blood mononuclear cells and serum level of interleukin-22 (IL-22) in patients with type 2 diabetes mellitus (T2DM).
Methods A total of 49 patients with pre-diabetes mellitus, 48 patients with T2DM and 50 healthy controls were respectively included in pre-diabetes group, T2DM group and control group. The expression of AhR mRNA in peripheral blood mononuclear cells was determined by reverse transcription polymerase chain reaction (RT-PCR); serum IL-22 level was detected by enzyme-linked immunosorbent assay (ELISA) in each group. Fasting blood glucose (FBG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), cholesterol (CHO), triglyceride (TG), fasting insulin (FINS), postprandial glucose (PPG), glycosylatedhemoglobin (HbA1c) and hypersensitive C-reactive protein (hs-CRP) were measured in each group.
Results Levels of FBG, TG, PPG, HbA1c and hs-CRP in the pre-diabetes group and the T2DM group were significantly higher than those in the control group, and HDL-C in the T2DM group was significantly lower than that in the control group (P<0.01) levels of FBG, TG, PPG and HbA1c in the T2DM group were significantly higher than those in the pre-diabetes group, while the HDL-C level was significantly lower than that in the pre-diabetes group (P<0.05 or P<0.01). FINS and serum IL-22 in the pre-diabetes group were significantly higher than those in the control group (P<0.01); the FINS, serum IL-22 and relative expression of AhR mRNA in the T2DM group were significantly higher than those in the control group and the pre-diabetes group (P<0.01). Pearson correlation analysis showed that AhR mRNA and IL-22 had no correlations with age, CHO, TG, LDL-C and body mass index (P>0.05), but were positively correlated with FBG, FINS, PPG, HbA1c and hs-CRP (P<0.05 or P<0.01).
Conclusion Detection of AhR mRNA and IL-22 level have certain clinical significance in evaluating the disease condition and prognosis of T2DM patients, which indicate AhR mRNA and IL-22 may become new targets for the treatment of diabetes.
DownLoad: